These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 32019779)
41. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
42. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. Dorothée G; Vergnon I; El Hage F; Le Maux Chansac B; Ferrand V; Lécluse Y; Opolon P; Chouaib S; Bismuth G; Mami-Chouaib F J Immunol; 2005 Jun; 174(11):6888-97. PubMed ID: 15905531 [TBL] [Abstract][Full Text] [Related]
44. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047 [TBL] [Abstract][Full Text] [Related]
45. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998 [TBL] [Abstract][Full Text] [Related]
46. Specific recruitment of γδ regulatory T cells in human breast cancer. Ye J; Ma C; Wang F; Hsueh EC; Toth K; Huang Y; Mo W; Liu S; Han B; Varvares MA; Hoft DF; Peng G Cancer Res; 2013 Oct; 73(20):6137-48. PubMed ID: 23959855 [TBL] [Abstract][Full Text] [Related]
47. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918 [TBL] [Abstract][Full Text] [Related]
48. Distinct gene expression in human Vdelta1 and Vdelta2 gammadelta T cells following non-TCR agonist stimulation. Kress E; Hedges JF; Jutila MA Mol Immunol; 2006 May; 43(12):2002-11. PubMed ID: 16423401 [TBL] [Abstract][Full Text] [Related]
49. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184 [No Abstract] [Full Text] [Related]
50. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. Inman BA; Frigola X; Harris KJ; Kuntz SM; Lohse CM; Leibovich BC; Kwon ED J Immunol; 2008 Mar; 180(5):3578-84. PubMed ID: 18292585 [TBL] [Abstract][Full Text] [Related]
51. [The comparison between HIV-infected patients' Vdelta2 T cells expansion efficiencies by zoledronic acid and gammadelta TCR monoclonal antibody in vitro]. Xu W; Wu XL; Xie YX; Yang JL; Nie WM; Zhao M; Chen WW Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Dec; 26(6):442-5. PubMed ID: 23627025 [TBL] [Abstract][Full Text] [Related]
52. NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions. Cazzetta V; Bruni E; Terzoli S; Carenza C; Franzese S; Piazza R; Marzano P; Donadon M; Torzilli G; Cimino M; Simonelli M; Bello L; Villa A; Tan L; Ravens S; Prinz I; Supino D; Colombo FS; Lugli E; Marcenaro E; Vivier E; Della Bella S; Mikulak J; Mavilio D Cell Rep; 2021 Oct; 37(3):109871. PubMed ID: 34686325 [TBL] [Abstract][Full Text] [Related]
53. An enlarged subpopulation of T lymphocytes bearing two distinct gammadelta TCR in an HIV-positive patient. Taupin JL; Halary F; Déchanet J; Peyrat MA; Ragnaud JM; Bonneville M; Moreau JF Int Immunol; 1999 Apr; 11(4):545-52. PubMed ID: 10323207 [TBL] [Abstract][Full Text] [Related]
54. T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. Pulitzer M; Geller S; Kumar E; Frosina D; Moskowitz A; Horwitz S; Myskowski P; Kheterpal M; Chan A; Dogan A; Jungbluth A Histopathology; 2018 Oct; 73(4):653-662. PubMed ID: 29893430 [TBL] [Abstract][Full Text] [Related]
55. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Zhou J; Kang N; Cui L; Ba D; He W Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706 [TBL] [Abstract][Full Text] [Related]
57. Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a γδ T-cell subtype associated with good clinical outcome. Boufea K; González-Huici V; Lindberg M; Symeonides S; Oikonomidou O; Batada NN Life Sci Alliance; 2021 Jan; 4(1):. PubMed ID: 33268347 [TBL] [Abstract][Full Text] [Related]
58. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Pizzolato G; Kaminski H; Tosolini M; Franchini DM; Pont F; Martins F; Valle C; Labourdette D; Cadot S; Quillet-Mary A; Poupot M; Laurent C; Ysebaert L; Meraviglia S; Dieli F; Merville P; Milpied P; Déchanet-Merville J; Fournié JJ Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11906-11915. PubMed ID: 31118283 [TBL] [Abstract][Full Text] [Related]
59. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100 [TBL] [Abstract][Full Text] [Related]
60. Gammadelta T cells recognize tumor cells via CDR3delta region. Xu C; Zhang H; Hu H; He H; Wang Z; Xu Y; Chen H; Cao W; Zhang S; Cui L; Ba D; He W Mol Immunol; 2007 Jan; 44(4):302-10. PubMed ID: 16650897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]